New antibody aims to supercharge immune system against cancer

NCT ID NCT07610941

Recruiting now Disease control Sponsor: Mestag Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called MST-0312, designed to help the body's immune system fight cancer more effectively. It is being studied alone or with another cancer drug (pembrolizumab) in people with several types of solid tumors, including lung, melanoma, bladder, colorectal, and triple-negative breast cancer. The main goals are to check safety, find the right dose, and see if it shrinks tumors. This is the first time MST-0312 is given to humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MST-0312 (a bispecific antibody that stimulates the immune system to fight cancer)
What this could lead to: If successful, this could lead to a new treatment option for certain cancers like lung, melanoma, bladder, colorectal, and triple-negative breast cancer.
What could go wrong: This is a very early Phase 1 trial, the first time MST-0312 is tested in humans. It primarily checks safety and dosing, so it may not show strong anti-cancer effects. Side effects are unknown and could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer melanoma neoplasm non-small cell lung carcinoma triple-negative breast carcinoma urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER-NEOPLASMS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Clinica Universidad De Navarra
NOT_YET_RECRUITING

Madrid, 28027, Spain
Hospital Clinico Universitario De Valencia
NOT_YET_RECRUITING

Valencia, 46010, Spain
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITING

Barcelona, 08035, Spain
Hospital Universitario 12 De Octubre
NOT_YET_RECRUITING

Madrid, 28041, Spain
Hospital Universitario Fundacion Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Hospital Universitario Hm Sanchinarro
RECRUITING

Madrid, 28050, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.